BALB/cNj-Foxn1^nu/Gpt

BALB/c-Nude|Strain NO.D000521

Spontaneous Mutation

Product Type:
Quantity: - +
Sex:
Age:
Genotype:

BASIC INFORMATION

Strain Name:	BALB/cNj-Foxn1^nu/Gpt
Strain Number:	D000521
Official Symbol:	Foxn1
Strain Strategy:	D000521.BALB_c-Nude strain info.pdf
Official Full Name:	forkhead box N1
Also Known As:	D11Bhm185e,Fkh19,HFH-11,Hfh11,Whn,nu,nude
NCBI Number:	15218
MGI Number:	102949
Chromosome:	11
Research Areas:	immunodeficiency,Other immunodeficient strains
Strain Background:	[N000020] BALB/cJGpt
Modification Type:	Spontaneous Mutation
Inventory Status:	Live,Cryopreserved
Sale Status:	IF (Available for Distribution)
Health Status:	Specific pathogen free (SPF)
Health Report:	Please log in to view
Publications:	1. A dynamic DNA tetrahedron framework for active targeting 2. Highly efficient fabrication of functional hepatocyte spheroids by a magnetic system for the rescue of acute liver failure 3. DDX39B drives colorectal cancer progression by promoting the stability and nuclear translocation of PKM2 4. Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-beta/SMAD3 pathway 5. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to anti-angiogenics in colorectal cancer liver metastasis models 6. Generation of a live attenuated influenza A vaccine by proteolysis targeting 7. Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis 8. Bone morphogenetic protein 7 mediates stem cells migration and angiogenesis: therapeutic potential for endogenous pulp regeneration 9. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies 10. Epigenetic Dysregulation Induces Translocation of Histone H3 into Cytoplasm 11. NIR‐Activated Multimodal Photothermal/Chemodynamic/Magnetic Resonance Imaging Nanoplatform for Anticancer Therapy by Fe (II) Ions Doped MXenes (Fe‐Ti3C2)12. Polypeptide uploaded efficient nanophotosensitizers to overcome photodynamic resistance for enhanced anticancer therapy 13. Cell‐Released Magnetic Vesicles Capturing Metabolic Labeled Rare Circulating Tumor Cells Based on Bioorthogonal Chemistry 14. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage 15. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα 16. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells 17. Kinectin 1 promotes the growth of triple-negative breast cancer via directly co-activating NF-kappaB/p65 and enhancing its transcriptional activity 18. Smart Acid‐Activatable Self‐Assembly of Black Phosphorous as Photosensitizer to Overcome Poor Tumor Retention in Photothermal Therapy 19. Heat stress activates YAP/TAZ to induce the heat shock transcriptome 20. Integrated omics of metastatic colorectal cancer 21. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma 22. Clonal mutations activate the NF-κB pathway to promote recurrence of nasopharyngeal carcinoma 23. In Vivo Bioorthogonal Labeling of Rare-Earth Doped Nanoparticles for Improved NIR-II Tumor Imaging by Extracellular Vesicle-Mediated Targeting 24. Rational Design of pH-Activated Upconversion Luminescent Nanoprobes for Bioimaging of Tumor Acidic Microenvironment and the Enhancement of Photothermal Therapy 25. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer 26. MAP7D2 reduces CD8(+) cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer 27. The synergistic regulation of chondrogenesis by collagen-based hydrogels and cell co-culture 28. Human cancer cells generate spontaneous calcium transients and intercellular waves that modulate tumor growth 29. TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma 30. Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation 31. ATF4-dependent fructolysis fuels growth of glioblastoma multiforme 32. Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system 33. Biomimetic nanoparticles drive the mechanism understanding of shear-wave elasticity stiffness in triple negative breast cancers to predict clinical treatment 34. Orthogonal excitations of lanthanide nanoparticle up/down conversion emissions via switching NIR lights for in-vivo theranostics 35. A carbon monoxide releasing metal organic framework nanoplatform for synergistic treatment of triple-negative breast tumors 36. Nuclear localization of mitochondrial TCA cycle enzymes modulates pluripotency via histone acetylation 37. CircNTNG1 inhibits renal cell carcinoma progression via HOXA5-mediated epigenetic silencing of Slug 38. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin 39. Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs 40. The chromatin remodeler CHD6 promotes colorectal cancer development by regulating TMEM65-mediated mitochondrial dynamics via EGF and Wnt signaling 41. BGN/FAP/STAT3 positive feedback loop mediated mutual interaction between tumor cells and mesothelial cells contributes to peritoneal metastasis of gastric cancer 42. A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers 43. Phosphomevalonate Kinase Controls beta-Catenin Signaling via the Metabolite 5-Diphosphomevalonate 44. Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations 45. Reprogramming of palmitic acid induced by dephosphorylation of ACOX1 promotes beta-catenin palmitoylation to drive colorectal cancer progression 46. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression 47. Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells 48. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy 49. Modulating tumor-stromal crosstalk via a redox-responsive nanomedicine for combination tumor therapy 50. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia 51. Nano-magnetic aptamer sensor incorporating AND logic recognition-launched hybridization chain reaction for organ origin identification of circulating tumor cells 52. CTSG Suppresses Colorectal Cancer Progression through Negative Regulation of Akt/mTOR/Bcl2 Signaling Pathway 53. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1 54. Stimuli-responsive heparin-drug conjugates co-assembled into stable nanomedicines for cancer therapy 55. The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma 56. PIBF1 regulates multiple gene expression via impeding long-range chromatin interaction to drive the malignant transformation of HPV16 integration epithelial cells 57. Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy 58. SEL1L-HRD1 endoplasmic reticulum-associated degradation controls STING-mediated innate immunity by limiting the size of the activable STING pool 59. SUMO specific peptidase 3 halts pancreatic ductal adenocarcinoma metastasis via deSUMOylating DKC1 60. Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP signaling 61. Autonomous metal-organic framework nanorobots for active mitochondria-targeted cancer therapy 62. B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma 63. Non-canonical role of UCKL1 on ferroptosis defence in colorectal cancer 64. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1 65. Cellular hierarchy framework based on single-cell/multi-patient sample sequencing reveals metabolic biomarker PYGL as a therapeutic target for HNSCC 66. Chronic stress accelerates glioblastoma progression via DRD2/ERK/beta-catenin axis and Dopamine/ERK/TH positive feedback loop 67. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer 68. Targeting CD36 determines nicotine derivative NNK-induced lung adenocarcinoma carcinogenesis 69. A biomimetic nanoreactor for combinational chemo/chemodynamic therapy of choriocarcinoma through synergistic apoptosis and ferroptosis strategy 70. CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression 71. FDW028, a novel FUT8 inhibitor, impels lysosomal proteolysis of B7-H3 via chaperone-mediated autophagy pathway and exhibits potent efficacy against metastatic colorectal cancer 72. FOXP1-GINS1 axis promotes DLBCL proliferation and directs doxorubicin resistance 73. HSP105 suppresses the progression of cutaneous squamous cell carcinoma by activating the P53 signaling pathway 74. Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma 75. Loss of NSUN6 inhibits osteosarcoma progression by downregulating EEF1A2 expression and activation of Akt/mTOR signaling pathway via m(5)C methylation 76. PC4-mediated Ku complex PARylation facilitates NHEJ-dependent DNA damage repair 77. A mitochondrial EglN1-AMPKalpha axis drives breast cancer progression by enhancing metabolic adaptation to hypoxic stress 78. A safety study on ultra‑high or moderate static magnetic fields combined with platycodin D against lung cancer 79. CLASRP oncogene as a novel target for colorectal cancer 80. DAB2IP suppresses invadopodia formation through destabilizing ALK by interacting with USP10 in breast cancer 81. ELOA promotes tumor growth and metastasis by activating RBP1 in gastric cancer 82. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer 83. In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy 84. LAD1 promotes malignant progression by diminishing ubiquitin-dependent degradation of vimentin in gastric cancer 85. LINC00955 suppresses colorectal cancer growth by acting as a molecular scaffold of TRIM25 and Sp1 to Inhibit DNMT3B-mediated methylation of the PHIP promoter 86. Long-read sequencing reveals the landscape of aberrant alternative splicing and novel therapeutic target in colorectal cancer 87. Single-cell RNA reveals a tumorigenic microenvironment in the interface zone of human breast tumors 88. Thymidylate synthase promotes esophageal squamous cell carcinoma growth by relieving oxidative stress through activating nuclear factor erythroid 2-related factor 2 expression 89. Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway 90. Design, Synthesis, and Biological Evaluation of a Novel [(18)F]-Labeled Arginine Derivative for Tumor Imaging 91. Dual network analysis of transcriptome data for discovery of new therapeutic targets in non-small cell lung cancer 92. Ginsenoside Rh4 inhibits inflammation-related hepatocellular carcinoma progression by targeting HDAC4/IL-6/STAT3 signaling 93. Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis 94. High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote malignant progression in lung adenocarcinoma 95. LINC00922 decoys SIRT3 to facilitate the metastasis of colorectal cancer through up-regulation the H3K27 crotonylation of ETS1 promoter 96. LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p/SOX4 axis and activating IFNgamma-JAK2-STAT1 pathway 97. M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1 98. Overexpression of HSPB6 inhibits osteosarcoma progress through the ERK signaling pathway 99. PHACTR1 promotes the mobility of papillary thyroid carcinoma cells by inducing F-actin formation 100. PRMT1 accelerates cell proliferation, migration, and tumor growth by upregulating ZEB1/H4R3me2as in thyroid carcinoma 101. RACK1 facilitates breast cancer progression by competitively inhibiting the binding of beta-catenin to PSMD2 and enhancing the stability of beta-catenin 102. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation 103. SECTM1 promotes the development of glioblastoma and mesenchymal transition by regulating the TGFβ1/Smad signaling pathway 104. Silencing GMPPB Inhibits the Proliferation and Invasion of GBM via Hippo/MMP3 Pathways 105. Targeting the SOX2/CDP protein complex with a peptide suppresses the malignant progression of esophageal squamous cell carcinoma 106. TBX3 promotes the epithelial mesenchymal transition of cervical cancer by upregulating ID1 107. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy 108. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers 109. USP36 stabilizes nucleolar Snail1 to promote ribosome biogenesis and cancer cell survival upon ribotoxic stress 110. WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2 111. Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progression 112. Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma 113. Cooperation of MLL1 and Jun in controlling H3K4me3 on enhancers in colorectal cancer 114. Epidermal-dermal coupled spheroids are important for tissue pattern regeneration in reconstituted skin explant cultures 115. HILPS, a long noncoding RNA essential for global oxygen sensing in humans 116. Hsa_circ_0020134 promotes liver metastasis of colorectal cancer through the miR-183-5p-PFN2-TGF-beta/Smad axis 117. Multiomic analysis of cervical squamous cell carcinoma identifies cellular ecosystems with biological and clinical relevance 118. PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies 119. SOX8 promotes tumor growth and metastasis through FZD6-dependent Wnt/beta-catenin signaling in colorectal carcinoma 120. Specific intracellular retention of circSKA3 promotes colorectal cancer metastasis by attenuating ubiquitination and degradation of SLUG 121. SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma 122. Synaptotagmin 1 Suppresses Colorectal Cancer Metastasis by Inhibiting ERK/MAPK Signaling-Mediated Tumor Cell Pseudopodial Formation and Migration 123. The diapause-like colorectal cancer cells induced by SMC4 attenuation are characterized by low proliferation and chemotherapy insensitivity 124. The m(7)G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling 125. Tousled-like kinase 1 promotes gastric cancer progression by regulating the tumor growth factor-beta signaling pathway 126. TSTA3 overexpression promotes malignant characteristics in LUSC by regulating LAMP2-mediated autophagy and tumor microenvironment 127. Upregulation of RSPO3 via targeted promoter DNA demethylation inhibits the progression of cholangiocarcinoma 128. ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape 129. ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3 130. Circular RNA circXPO1 Promotes Multiple Myeloma Progression by Regulating miR-495-3p/DNA Damage-Induced Transcription 4 Axis 131. Essential genes analysis reveals small ribosomal subunit protein eS28 may be a prognostic factor and potential vulnerability in osteosarcoma 132. Exploring the potential of carbon-coated MoSe2 nanoparticles as a photothermal therapy for ovarian cancer 133. HOMER3 promotes non-small cell lung cancer growth and metastasis primarily through GABPB1-mediated mitochondrial metabolism 134. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma 135. Metformin Suppresses Stemness of Non-Small-Cell Lung Cancer Induced by Paclitaxel through FOXO3a 136. PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors 137. POU5F1 promotes the proliferation, migration, and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6 138. Predictive role of E2F6 in cancer prognosis and responses of immunotherapy 139. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer 140. Single-particle analysis of circulating bacterial extracellular vesicles reveals their biogenesis, changes in blood and links to intestinal barrier 141. S-Nitrosylation-mediated coupling of DJ-1 with PTEN induces PI3K/AKT/mTOR pathway-dependent keloid formation 142. Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1 143. Exogenous carbon monoxide promotes GPX4-dependent ferroptosis through ROS/GSK3beta axis in non-small cell lung cancer 144. ID2 promotes tumor progression and metastasis in thyroid cancer 145. Regulation of tumor metastasis and CD8(+) T cells infiltration by circRNF216/miR-576-5p/ZC3H12C axis in colorectal cancer 146. ALKBH5 is a prognostic factor and promotes the angiogenesis of glioblastoma 147. WNT7A promotes tumorigenesis of head and neck squamous cell carcinoma via activating FZD7/JAK1/STAT3 signaling 148. Baicalin alleviates chronic stress-induced breast cancer metastasis via directly targeting β2-adrenergic receptor 149. The miR-19a/Cylindromatosis Axis Regulates Pituitary Adenoma Bone Invasion by Promoting Osteoclast Differentiation 150. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2alpha blockade by facilitating LDHA phosphorylation 151. Downregulation of Rab23 inhibits hepatocellular carcinoma by repressing SHH signaling pathway 152. Jinfukang inhibits lung cancer metastasis by regulating T cell receptors 153. Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting 154. Ellagic acid inhibits tumor growth and potentiates the therapeutic efficacy of sorafenib in hepatocellular carcinoma 155. Targeting DAD1 gene with CRISPR-Cas9 system transmucosally delivered by fluorinated polylysine nanoparticles for bladder cancer intravesical gene therapy 156. Protein disulfide isomerase family member 4 promotes triple-negative breast cancer tumorigenesis and radiotherapy resistance through JNK pathway 157. ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell Carcinoma 158. Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain 159. Self-propelled assembly of nanoparticles with self-catalytic regulation for tumour-specific imaging and therapy 160. Proteomic analysis reveals LRPAP1 as a key player in the micropapillary pattern metastasis of lung adenocarcinoma 161. SECTM1 promotes the development of glioblastoma and mesenchymal transition by regulating the TGFbeta1/Smad signaling pathway 162. MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning 163. CYB561 promotes HER2+ breast cancer proliferation by inhibiting H2AFY degradation 164. Superbinder based phosphoproteomic landscape revealed PRKCD_pY313 mediates the activation of Src and p38 MAPK to promote TNBC progression 165. Radiotherapy-Induced Astrocyte Senescence Promotes an Immunosuppressive Microenvironment in Glioblastoma to Facilitate Tumor Regrowth 166. Synergism of non-thermal plasma and low concentration RSL3 triggers ferroptosis via promoting xCT lysosomal degradation through ROS/AMPK/mTOR axis in lung cancer cells 167. Ailanthone synergizes with PARP1 inhibitor in tumour growth inhibition through crosstalk of DNA repair pathways in gastric cancer 168. Pan-cancer analysis of ABCC1 as a potential prognostic and immunological biomarker 169. Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells 170. ELF4 contributes to esophageal squamous cell carcinoma growth and metastasis by augmenting cancer stemness via FUT9 171. SLC25A17 inhibits autophagy to promote triple-negative breast cancer tumorigenesis by ROS-mediated JAK2/STAT3 signaling pathway 172. Vasorin exocytosed from glioma cells facilitates angiogenesis via VEGFR2 AKT signaling pathway 173. Urocortin-1 promotes colorectal cancer cell migration and proliferation and inhibits apoptosis via inhibition of the p53 signaling pathway 174. Transmembrane protein 176B regulates amino acid metabolism through the PI3K-Akt-mTOR signaling pathway and promotes gastric cancer progression 175. Unraveling the molecular mechanisms of lymph node metastasis in ovarian cancer: focus on MEOX1 176. Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer 177. Abnormal upregulation of NUBP2 contributes to cancer progression in colorectal cancer 178. Activation of the FOXM1/ASF1B/PRDX3 axis confers hyperproliferative and antioxidative stress reactivity to gastric cancer 179. PELI1: key players in the oncogenic characteristics of pancreatic Cancer 180. NSUN2 promotes colorectal cancer progression by enhancing SKIL mRNA stabilization 181. Membrane-associated RING-CH 7 inhibits stem-like capacities of bladder cancer cells by interacting with nucleotide-binding oligomerization domain containing 1 182. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway 183. FBXO22 promotes glioblastoma malignant progression by mediating VHL ubiquitination and degradation 184. FTO-mediated autophagy inhibition promotes non-small cell lung cancer progression by reducing the stability of SESN2 mRNA 185. GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism 186. Cyclin-dependent kinase inhibitor 1A inhibits pyroptosis to enhance human lung adenocarcinoma cell radioresistance by promoting DNA repair 187. BZW2 promotes malignant progression in lung adenocarcinoma through enhancing the ubiquitination and degradation of GSK3beta 188. Characterization of AST-001 non-clinical pharmacokinetics: A novel selective AKR1C3-activated prodrug in mice, rats, and cynomolgus monkeys 189. Accumulation of TOX high mobility group box family member 3 promotes the oncogenesis and development of hepatocellular carcinoma through the MAPK signaling pathway 190. Self-Assembled DNA Composite-Engineered Mesenchymal Stem Cells for Improved Skin-Wound Repair 191. TNF-alpha-Induced KAT2A Impedes BMMSC Quiescence by Mediating Succinylation of the Mitophagy-Related Protein VCP 192. Activation of CTU2 expression by LXR promotes the development of hepatocellular carcinoma 193. Blockade of the deubiquitinating enzyme USP48 degrades oncogenic HMGA2 and inhibits colorectal cancer invasion and metastasis 194. Anticancer potential of grifolin in lung cancer treatment through PI3K/AKT pathway inhibition 195. APLN promotes the proliferation, migration, and glycolysis of cervical cancer through the PI3K/AKT/mTOR pathway 196. Augmented ERO1alpha upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11 197. Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis 198. DMC-siERCC2 hybrid nanoparticle enhances TRAIL sensitivity by inducing cell cycle arrest for glioblastoma treatment 199. C-IGF1R encoded by cIGF1R acts as a molecular switch to restrict mitophagy of drug-tolerant persister tumour cells in non-small cell lung cancer 200. Diaphorobacter nitroreducens synergize with oxaliplatin to reduce tumor burden in mice with lung adenocarcinoma.201. DNMT1/miR-152-3p/SOS1 signaling axis promotes self-renewal and tumor growth of cancer stem-like cells derived from non-small cell lung cancer 202. Frequent loss of FAM126A expression in colorectal cancer results in selective FAM126B dependency 203. The pan-RAF-MEK non degrading molecular glue NST-628 is a potent and brain penetrant inhibitor of the RAS-MAPK pathway with activity across diverse RAS-and RAF-driven cancers 204. Tyrosine hydroxylase inhibits HCC progression by downregulating TGFbeta/Smad signaling 205. 20(S)-ginsenoside Rh2 ameliorates ATRA resistance in APL by modulating lactylation-driven METTL3 206. Agaricus blazei murrill and Enteromorpha prolifera-derived polysaccharides gain therapeutic effects on esophageal squamous cell carcinoma 207. Autocrine and Paracrine Effects of MDK Promote Lymph Node Metastasis of Cervical Squamous Cell Carcinoma 208. Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner 209. BHLHE41 inhibits bladder cancer progression via regulation of PYCR1 stability and thus inactivating PI3K/AKT signaling pathway 210. Blockade of a novel MAP4K4-LATS2-SASH1-YAP1 cascade inhibits tumorigenesis and metastasis in luminal breast cancer 211. CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis 212. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer 213. Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions 214. Development of a Specific Aptamer-Modified Nano-System to Treat Esophageal Squamous Cell Carcinoma 215. Enhancing antitumor efficacy of oncolytic virus M1 via albendazole-sustained CD8(+) T cell activation 216. Ethanol Extracted from Radix of Actinidia Chinensis Inhibits Human Colon Tumor Through Inhibiting Notch-signaling Pathway 217. Energy stress-induced circDDX21 promotes glycolysis and facilitates hepatocellular carcinogenesis 218. Epigenetic silencing of LDHB promotes hepatocellular carcinoma by remodeling the tumor microenvironment 219. Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 220. LARP4B promotes hepatocellular carcinoma progression and impairs sorafenib efficacy by activating SPINK1-mediated EGFR pathway 221. Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study 222. O-GlcNAcylation Facilitates the Interaction between Keratin 18 and Isocitrate Dehydrogenases and Potentially Influencing Cholangiocarcinoma Progression 223. NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis 224. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma 225. Phenazine derivatives attenuate the stemness of breast cancer cells through triggering ferroptosis 226. Ternary heterostructure-driven photoinduced electron-hole separation enhanced oxidative stress for triple-negative breast cancer therapy 227. The therapeutic effect and targets of herba Sarcandrae on breast cancer and the construction of a prognostic signature consisting of inflammation-related genes 228. Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth 229. Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer 230. Single-Cell Chromatin Accessibility Analysis Reveals Subgroup-Specific TF-NTR Regulatory Circuits in Medulloblastoma 231. Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer 232. ETV4 promotes the progression of cholangiocarcinoma by regulating glycolysis via the TGF-beta signaling 233. Identification of an osteopontin-derived peptide that binds neuropilin-1 and activates vascular repair responses and angiogenesis 234. NEDD4L mediates ITGB4 ubiquitination and degradation to suppress esophageal carcinoma progression 235. OTUB1 Promotes Glioblastoma Growth by Inhibiting the JAK2/STAT1 Signaling Pathway 236. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma 237. Can thymosin beta 10 function both as a non-invasive biomarker and chemotherapeutic target in human colorectal cancer?238. Genomic profiling of a multi-lineage and multi-passage patient-derived xenograft biobank reflects heterogeneity of ovarian cancer 239. Deacetylation of GLUD1 maintains the survival of lung adenocarcinoma cells under glucose starvation by inhibiting autophagic cell death 240. Decoding sunitinib resistance in ccRCC: Metabolic-reprogramming-induced ABAT and GABAergic system shifts 241. Identification of TEFM as a potential therapeutic target for LUAD treatment 242. Identification of SLC7A11-AS1/SLC7A11 pair as a ferroptosis-related therapeutic target for hepatocellular carcinoma 243. IKIP downregulates THBS1/FAK signaling to suppress migration and invasion by glioblastoma cells 244. lncRNA-WAL promotes triple-negative breast cancer aggression by inducing β-catenin nuclear translocation.245. Intravesical cascade delivery of active monoterpene coumarin for bladder cancer therapy 246. NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer 247. Peptidyl-prolyl isomerase F as a prognostic biomarker associated with immune infiltrates and mitophagy in lung adenocarcinoma 248. Positive feedback loop of c-myc/XTP6/NDH2/NF-kappaB to promote malignant progression in glioblastoma 249. Nuclear translocation of ISG15 regulated by PPP2R2B inhibits cisplatin resistance of bladder cancer 250. Phase separation of RNF214 promotes the progression of hepatocellular carcinoma 251. The recruitment of CD8(+) T cells through YBX1 stabilization abrogates tumor intrinsic oncogenic role of MIR155HG in lung adenocarcinoma 252. NOP2 facilitates EZH2-mediated epithelial-mesenchymal transition by enhancing EZH2 mRNA stability via m5C methylation in lung cancer progression 253. Directed differentiation of pancreatic delta cells from human pluripotent stem cells 254. The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers 255. Zinc finger protein 180 induces an apoptotic phenotype by activating METTL14 transcriptional activity in colorectal cancer 256. Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer 257. Suppression of pathological neovascularization by anti-Flt1 peptide functionalized DNA tetrahedron 258. A positive feedback loop between PFKP and c-Myc drives head and neck squamous cell carcinoma progression 259. Tumor-intrinsic P2RY6 drives immunosuppression by enhancing PGE(2) production 260. Synthetic lethality of combined ULK1 defection and p53 restoration induce pyroptosis by directly upregulating GSDME transcription and cleavage activation through ROS/NLRP3 signaling 261. USP4-mediated CENPF deubiquitylation regulated tumor metastasis in colorectal cancer 262. Single‐Cell Chromatin Accessibility Analysis Reveals Subgroup‐Specific TF‐NTR Regulatory Circuits in Medulloblastoma 263. Bioorthogonal Diels-Alder Click Chemistry-Based Pretargeted PET Imaging Strategy for Monitoring Programmed Death-Ligand 1 Expression 264. RUNX1-PDIA5 Axis Promotes Malignant Progression of Glioblastoma by Regulating CCAR1 Protein Expression 265. Baicalin reduces chronic stress-induced breast cancer metastasis via directly targeting beta2-adrenergic receptor 266. Polydopamine-Based Targeted Nanosystem for Chemo/Photothermal Therapy of Retinoblastoma in a Mouse Orthotopic Model 267. DNA self-assembly-mediated high drug-antibody ratio ADC platform for targeted tumor therapy and imaging 268. Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer 269. Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy 270. SelK promotes glioblastoma cell proliferation by inhibiting beta-TrCP1 mediated ubiquitin-dependent degradation of CDK4 271. HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing 272. Fibrillarin reprograms glucose metabolism by driving the enhancer-mediated transcription of PFKFB4 in liver cancer 273. Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer 274. Stepwise-targeting and hypoxia-responsive liposome AMVY@NPs carrying siYAP and verteporfin for glioblastoma therapy 275. Selenium-Doped Nanoheterojunctions for Highly Efficient Cancer Radiosensitization 276. Three-in-One: Molecular Engineering of D-A-pi-A Featured Type I and Type II Near-Infrared AIE Photosensitizers for Efficient Photodynamic Cancer Therapy and Bacteria Killing 277. Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway 278. ETHE1 dampens colorectal cancer angiogenesis by promoting TC45 Dephosphorylation of STAT3 to inhibit VEGF-A expression 279. Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1 280. Therapeutic targeting ERRgamma suppresses metastasis via extracellular matrix remodeling in small cell lung cancer 281. HDAC2 promotes autophagy-associated HCC malignant progression by transcriptionally activating LAPTM4B 282. PTBP1 knockdown impairs autophagy flux and inhibits gastric cancer progression through TXNIP-mediated oxidative stress 283. SVIP reduces IGFBP-2 expression and inhibits glioblastoma progression via stabilizing PTEN 284. LncRNA HOXB-AS3 promotes proliferation, migration, and invasion of gallbladder cancer cells by activating the MEK/ERK pathway 285. UCK2 promotes intrahepatic cholangiocarcinoma progression and desensitizes cisplatin treatment by PI3K/AKT/mTOR/autophagic axis 286. The role of BUD31 in clear cell renal cell carcinoma: prognostic significance, alternative splicing, and tumor immune environment 287. MVP enhances FGF21-induced ferroptosis in hepatocellular carcinoma by increasing lipid peroxidation through regulation of NOX4 288. MANF facilitates breast cancer cell survival under glucose-starvation conditions via PRKN-mediated mitophagy regulation 289. Engineered exosomes transporting the lncRNA, SVIL-AS1, inhibit the progression of lung cancer via targeting miR-21-5p 290. S-Doped Hollow Multi-Metallic Prussian Blue Analogue (PBA) Nanoplatform for Enhanced Anticancer for Cervical Cancer 291. Prohibitin 2 confers NADPH oxidase 1-mediated cytosolic oxidative signaling to promote gastric cancer progression by ERK activation 292. METTL3 Inhibition Suppresses Cell Growth and Survival in Colorectal Cancer via ASNS Downregulation 293. Cold atmospheric plasma enhances SLC7A11-mediated ferroptosis in non-small cell lung cancer by regulating PCAF mediated HOXB9 acetylation 294. Identifying and validating the roles of the cuproptosis-related gene DKC1 in cancer with a focus on esophageal carcinoma 295. FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation 296. Core-Shell Interface Engineering Strategies for Modulating Energy Transfer in Rare Earth-Doped Nanoparticles 297. HOXA9 promotes proliferation, metastasis and prevents apoptosis in hepatocellular carcinoma 298. Hypoxia-induced BAP1 enhances erastin-induced ferroptosis in nasopharyngeal carcinoma by stabilizing H2A 299. RUNX1-MUC13 Interaction Activates Wnt/β-Catenin Signaling Implications for Colorectal Cancer Metastasis 300. The microprotein HDSP promotes gastric cancer progression through activating the MECOM-SPINK1-EGFR signaling axis 301. Prohibitin 2 orchestrates long noncoding RNA and gene transcription to accelerate tumorigenesis 302. FHL2 activates β-catenin/Wnt signaling by complexing with APC and TRIM63 in lung adenocarcinoma 303. DUS4L suppresses invasion and metastasis in LUAD via modulation of PI3K/AKT and ERK/MAPK signaling through GRB2 304. NEDD9 is transcriptionally regulated by HDAC4 and promotes breast cancer metastasis and macrophage M2 polarization via the FAK/NF-κB signaling pathway 305. Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer 306. SCAMP1 silencing inhibits proliferation by attenuating multiple pro-survival signaling pathways in gastric cancer 307. CLK3 promotes tumor proliferation by activating MYC signaling 308. Therapeutic targeting ERRγ suppresses metastasis via extracellular matrix remodeling in small cell lung cancer 309. DDR1 Drives Malignant Progression of Gastric Cancer by Suppressing HIF‐1α Ubiquitination and Degradation 310. CircSP3 encodes SP3-461aa to promote ccRCC progression via stabilizing MYH9 and activating the PI3K-Akt signaling pathway 311. Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation 312. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors 313. Combined miR-181a-5p and Ag Nanoparticles are Effective Against Oral Cancer in a Mouse Model 314. Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production 315. PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation 316. MYO3B promotes cancer progression in endometrial cancer by mediating the calcium ion-RhoA/ROCK1 signaling pathway 317. Lanthanum-based dendritic mesoporous nanoplatform for tumor microenvironment activating synergistic anti-glioma efficacy 318. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer 319. Chlorogenic acid exhibits antitumor effect in patient-derived xenograft models and hydrogel-embedded tissue culture drug susceptibility test of tongue cancer 320. LMP1 enhances aerobic glycolysis in natural killer/T cell lymphoma 321. ACSL6-activated IL-18R1–NF-κB promotes IL-18–mediated tumor immune evasion and tumor progression.322. Enhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer 323. METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma 324. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models 325. DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression 326. Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC 327. Nanobody-Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING-Mediated Anti-Tumor Immunity 328. Zdhhc1- and Zdhhc2-mediated Gpm6a palmitoylation is essential for maintenance of mammary stem cell activity 329. FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity
Gene Family:	Forkhead boxes